AC
RDHL

Annandale Capital’s Redhill Biopharma RDHL Stock Holding History

Annandale Capital’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$4K – 141
2022
Q4 		$4K Buy
+25
New +$10.8K ﹤0.01% 136
2022
Q3 		– Sell
-44
Closed -$38K – 155
2022
Q2 		$38K Hold
44
– – 0.02% 126
2022
Q1 		$110K Hold
44
– – 0.04% 111
2021
Q4 		$112K Hold
44
– – 0.05% 112
2021
Q3 		$199K Hold
44
– – 0.12% 80
2021
Q2 		$300K Hold
44
– – 0.18% 69
2021
Q1 		$319K Hold
44
– – 0.23% 54
2020
Q4 		$352K Buy
+44
New +$396K 0.29% 40

Other funds holding RDHL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Annandale Capital's RDHL Position: Q1 2023 in Review

Annandale Capital sold out of Redhill Biopharma (RDHL) in Q1 2023, closing a stake of 25 shares — an estimated $4K sold.

Annandale Capital first reported a position in RDHL in Q4 2020 and held it in 8 quarters. The position peaked at $352K in Q4 2020. 16 funds tracked by Wall St. Rank hold RDHL as of Q1 2023.

  • Annandale Capital reported no remaining Redhill Biopharma position as of Q1 2023 after selling out during the quarter.
  • Annandale Capital sold 25 Redhill Biopharma shares in Q1 2023, an estimated $4K.
  • Annandale Capital first reported a position in Redhill Biopharma in Q4 2020 and held it in 8 quarters.
  • Annandale Capital's Redhill Biopharma position peaked at $352K in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2023.

Based on Annandale Capital's 13F filing for Q1 2023, filed 15 May 2023.